Niner Pharmaceuticals expands global peptide and oncology API network

By AI, Created 11:26 AM UTC, June 03, 2026, /AGP/ – Niner Pharmaceuticals says it is widening its international supply network to meet rising demand for research-grade peptides, oncology APIs and other life sciences products. The Dubai-based company is also developing an AI-powered product intelligence platform as it targets broader growth across North America, Europe, the Middle East and Asia.

Why it matters: - Niner Pharmaceuticals is positioning itself as a broader supplier for pharmaceutical companies, research institutions, CDMOs, specialty distributors and healthcare organizations that need reliable access to specialized ingredients and documentation. - The expansion reflects growing demand for high-quality pharmaceutical ingredients and research compounds across global healthcare and life sciences markets. - The company’s growth in oncology APIs and advanced research products could improve supply continuity for buyers that depend on specialized sourcing.

What happened: - Niner Pharmaceuticals LLC announced the continued expansion of its global supply network. - The Dubai-headquartered company operates across the United Arab Emirates, the United States, Hong Kong and India. - Niner Pharmaceuticals said it now offers more than 150 custom peptides, plus oncology active pharmaceutical ingredients, biologicals and advanced research compounds. - The company said its products are supported by Certificates of Analysis, HPLC chromatograms and quality verification protocols. - Founder and CEO Jamie Balaji Rao said the company is focused on quality, transparency and operational excellence. - Niner Pharmaceuticals said its warehousing and logistics operations are designed to support efficient delivery across key markets. - The company said its oncology API division serves pharmaceutical manufacturers, specialty distributors, research organizations and healthcare partners. - Niner Pharmaceuticals is also expanding in biologicals, regenerative medicine research and exosome-related product categories. - The company is developing PeptideIQ, an AI-powered product intelligence platform. - The platform is intended to give customers more visibility into product specifications, quality documentation, batch analytics and procurement information. - The company plans to expand further across North America, Europe, the Middle East and Asia over the next several years.

The details: - Niner Pharmaceuticals said its international distribution network is built to support supply continuity and streamlined procurement. - The company said its infrastructure is designed to provide access to critical products and documentation for institutional buyers and research professionals. - Niner Pharmaceuticals described its portfolio as including research-grade peptides, oncology APIs, biologicals, exosomes and specialized life sciences products. - The company said it will continue investing in quality assurance, operational infrastructure and technology-driven solutions.

Between the lines: - Niner Pharmaceuticals is signaling a move from product supplier toward a more integrated sourcing and information partner. - The push into AI-enabled product intelligence suggests the company sees documentation, batch data and procurement visibility as part of the competitive edge. - The focus on multiple regions indicates the company is trying to reduce dependence on any single market while broadening its buyer base.

What’s next: - Niner Pharmaceuticals plans to keep building its presence in major global markets. - The company expects continued investment in quality systems and logistics capabilities. - PeptideIQ will be a key test of whether the company can pair product supply with higher-value digital tools.

The bottom line: - Niner Pharmaceuticals is expanding beyond distribution into a wider global platform for specialized pharmaceutical ingredients, documentation and research support.